Intimate Conversations and Strategic Perspectives
AI plays a major role throughout the life science value chain. From drug discovery and development to clinical and market analytics, experts utilize AI to deliver actionable insights and empower decision-making. The AI in life sciences market is expected to grow from $2.8 billion in 2024 to $13.8 billion by 2034, signaling how AI is transforming how innovation is driven across the sector.
But with such explosive growth in the market, how can the Nordics best position themselves to capitalize on this momentum?
This opportunity was brought into vivid focus on June 2025, when Evalueserve hosted an exclusive executive dinner in Copenhagen. Bringing together senior leaders from across the Nordic biotech, pharmaceutical, diagnostics, and healthcare services sectors. Against the backdrop of exquisite cuisine, guests exchanged perspectives on how innovation, AI, and strategic partnerships are not only transforming the life sciences landscape — but positioning the Nordics to become a powerhouse of AI-driven healthcare and biotech innovation.
Key Themes from the Evening
AI as a Strategic Collaborator
The conversation confirmed a growing trend: AI is no longer a peripheral tool—it’s becoming a central collaborator in drug development, diagnostics, and commercial strategy. From accelerating clinical trial timelines to improving real-world data interpretation, AI is reshaping what is possible in life sciences innovation.
Evolving Commercial and Market Access Models
As market dynamics evolve, life sciences leaders are actively rethinking commercialization strategies. Guests emphasized the role of integrated data, local insights, and agile market access models—especially in value-based healthcare systems like those in the Nordics.
RWE and Personalized Medicine
Real-world evidence continues to gain traction, not just as a regulatory requirement but as a driver of patient-centric innovation. With the continued rise of precision medicine, the ability to effectively integrate RWE into clinical and commercial decision-making is becoming a competitive differentiator.
Partnering in the Age of AI
Strategic partnerships are shifting—from transactional to transformational. Companies are looking beyond traditional alliances to form innovation-driven collaborations that unlock new capabilities, particularly in data science, AI, and digital health.
A Shared Commitment to Innovation in the Nordics
The evening highlighted how AI is rapidly becoming a catalyst for innovation within the Nordic life sciences industry. What emerged from our discussions was a clear consensus: AI isn’t just a tool—it’s reshaping how organizations think, collaborate, and deliver value across the healthcare ecosystem.
We thank all the participants for their thoughtful contributions and open dialogue. We left the evening energized by the shared commitment to advancing science, improving outcomes, and driving meaningful change—together.
Evalueserve: Your Partner in AI-Driven Life Sciences Strategy
As AI and data become foundational to success in life sciences, Evalueserve supports clients with a unique combination of:
- Strategic Insights & Competitive Intelligence through our proprietary Insightsfirst platform, designed to track pipelines, competitors, and emerging therapies with precision.
- Advanced Analytics & AI Solutions to support clinical trial design, patient identification, and commercial optimization.
Our work across pharma, biotech, and diagnostics helps clients harness innovation to solve real-world challenges—today and for the future.
